The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Nov 2025

Sponsor / Collaborator

Duke University

[+4]

NCT05339256

/ Not yet recruitingPhase 2IIT

A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder

This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).

Start Date01 Jun 2025

Sponsor / Collaborator

The New York State Psychiatric Institute

[+1]

NCT06880718

/ Not yet recruitingPhase 4

Injectable Buprenorphine During Transition Out of Prison: a Partially Randomized Preference Pilot Trial

The goal of this pilot trial is to compare two branded extended-release buprenorphine (XR-B) formulations (Sublocade vs. Brixadi) to explore how they improve treatment retention after release from prison among incarcerated individuals with opioid use disorder (OUD) who are transitioning back into the community.
The main question it aims to answer are:
How do Sublocade and Brixadi compare in terms of feasibility, acceptability, and effectiveness? Does giving people a choice of medication affect how well they stay in treatment?
Using a partially randomized preference trial approach, there will be a comparison between participants who choose their XR-B formulation to those who are randomly assigned to see if patient preference influences treatment outcomes. The trial is a hybrid implementation-effectiveness trial.
Participants will:
* Choose which medication they prefer or be randomly assigned if they don't have a preference.
* Receive monthly injections of either Sublocade or Brixadi before and after release from prison.
* Complete surveys and clinical assessments on treatment experience and acceptability.
* Be monitored for treatment retention, opioid use, and adverse events for six months post-release.
Researchers will compare the two treatments to see which one works better for people leaving prison and if allowing people to choose their treatment improves results.

Start Date01 Jun 2025

Sponsor / Collaborator

Brown University Health

[+1]

100 Clinical Results associated with Buprenorphine

100 Translational Medicine associated with Buprenorphine

100 Patents (Medical) associated with Buprenorphine

8,706

Literatures (Medical) associated with Buprenorphine

01 Jun 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

The promising use of an emergency department observation unit to manage patients with opioid use disorder

Article

Author: Rosania, Anthony ; Dym, Akiva ; Ramdin, Christine ; Tran, Thai ; Imperato, Nicholas ; Nelson, Lewis ; Santos, Cynthia

INTRODUCTION:

The opioid epidemic continues to grow, placing a significant strain on Emergency Departments (EDs), resulting in patients presenting daily with opioid-related concerns including intoxication, withdrawal, infections, injury, and death. Consequently, in recent years many EDs, including our own, have utilized Emergency Department Observation Units (EDOU) to not only manage withdrawal and overdose, but also initiate long-term treatment. This study aims to evaluate the outcomes of patients with opioid use disorder (OUD) who were managed in our EDOU.

METHODS:

This was a retrospective study of patients placed in an EDOU who had the primary diagnosis of OUD in a single large, urban, tertiary academic hospital from May to November 2021. Demographic data and factors related to the ED visit and EDOU actions (e.g., use of peer navigator services, buprenorphine dose and prescription, distribution of naloxone discharge kits, and addiction clinic referral) were analyzed. The primary outcome variables were complications after buprenorphine use (e.g., precipitated withdrawal), the number of repeat ED visits or subsequent hospitalizations within 30 days for both all causes and opioid-related causes, and fatalities within 30 days of EDOU discharge.

RESULTS:

Twenty-nine patients were identified for chart review. Of these, 59 % were male. The median age was 55 years. Additionally, 93 % of the patients were insured, 66 % had housing, 72 % possessed a phone, and none were employed. During EDOU stays, 48 % [95 % CI 0.2989, 0.6711] of patients received buprenorphine with a total mean dose of 19 mg (SD, 10.6 mg). Upon discharge from the EDOU, 48 % [95 % CI 0.2989, 0.6711] were prescribed buprenorphine, 14 % [95 % CI 0.0451, 0.3257] received a naloxone discharge kit, and 45 % [95 % CI 0.2696, 0.6402] received an addiction clinic appointment. No patients had precipitated withdrawal, serious adverse events, or upgrades to inpatient care. Within 30-days of EDOU discharge, 38 % [95 % CI 0.213, 0.5764] of patients had a subsequent ED visit for any cause, and 6.9 % [95 % CI 1.2, 2.2] had a subsequent hospitalization for any cause. There were no fatalities within 30 days of EDOU discharge.

CONCLUSION:

The EDOU can serve as a promising location to provide quality care for patients presenting to the ED with OUD, with minimal adverse effects. There were few subsequent hospitalizations following discharge from the EDOU. Further non-observational studies regarding OUD management in an EDOU setting should be performed to optimize care and improve clinical outcomes and healthcare utilization.

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Xia, Bing ; Chen, Xiaoqi ; Zhou, Yan ; Zhang, Min

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 Jun 2025·NEUROPHARMACOLOGY

Prenatal exposure to methadone or buprenorphine alters transcriptional networks associated with synaptic signaling in newborn rats

Article

Author: Nyberg, Henriette ; Bogen, Inger Lise ; Duale, Nur ; Andersen, Jannike Mørch

While the use of methadone or buprenorphine during pregnancy is beneficial for the mother's health compared to illicit opioid use, prenatal exposure to these medications may have adverse consequences for the unborn child. However, the underlying molecular mechanisms of prenatal opioid exposure on neurodevelopment remain poorly understood. Hence, this study aimed to investigate gene expression changes, focusing on synapse-related genes, in cerebral tissue from newborn rats prenatally exposed to methadone or buprenorphine. Female Sprague-Dawley rats were exposed to methadone (10 mg/kg/day), buprenorphine (1 mg/kg/day), or sterile water through osmotic minipumps during pregnancy. Total RNA was isolated from the cerebrum on postnatal day 2 and analyzed using RNA-sequencing. Analyses of differentially expressed genes (DEGs) and enriched biological processes were conducted to compare the gene expression profiles between treatment groups within each sex. Prenatal buprenorphine exposure resulted in 598 DEGs (333 up- and 265 downregulated) in males and 175 (75 up- and 100 downregulated) in females, while prenatal methadone exposure resulted in 335 DEGs (224 up- and 111 downregulated) in males and 201 (57 up- and 144 downregulated) in females. Gene ontology analyses demonstrated that enriched biological processes included synaptic signaling, immune responses, and apoptosis. Analysis of the DEGs using the synapse database SynGO revealed that males prenatally exposed to buprenorphine displayed the highest number of enriched synapse-related biological process terms. Understanding gene expression changes following prenatal methadone or buprenorphine exposure is crucial to uncover the mechanisms underlying behavioral alterations and to develop interventions to mitigate the impact of opioid exposure on neurodevelopment.

News (Medical) associated with Buprenorphine

10 Apr 2025

·www.prnewswire.com

Newborn Brains Are Smaller When Exposed to Opioids During Gestation

An important "first dive" into data from the 4-site Outcomes of Babies with Opioid Exposure (OBOE) study features a Cincinnati Children's expert as co-first author CINCINNATI, April 10, 2025 /PRNewswire/ -- When pregnant women take opioids during pregnancy, even opioids such as buprenorphine or methadone to treat opioid use disorder, the developing brains of their children can be significantly affected, according to a study published April 7, 2025, in JAMA Pediatrics. Continue Reading Antenatal opioid exposure is associated with smaller neonatal brain volumes, with varying impact depending on the type and number of exposures, according to research published in JAMA Pediatrics. Stephanie Merhar, MD, MS, at Cincinnati Children's was first co-author. Total brain volume was nearly 5% smaller among 173 newborns with antenatal opioid exposure compared to 96 unexposed newborns, based on magnetic resonance imaging (MRI) scans. More specifically, reduced volumes among opioid-exposed newborns occurred in cortical gray matter, deep gray matter, white matter, cerebellum, brainstem, and the right and left amygdala. There were notable differences in the location and scale of the effects, which varied depending on the type of opioid involved, and whether other drugs were also taken during pregnancy. "We have known for a while that children exposed to opioids during pregnancy are at risk of later developmental and behavioral problems, but it was hard to know whether that was due to the opioids themselves or other factors such as other exposures or lower birth weight," says co-first author Stephanie Merhar, MD, MS, a neonatologist at Cincinnati Children's. "This study was launched because we needed a large study where we were able to control for things like nicotine exposure and birth weight. Our next step is to follow the children in the study to see whether having smaller brain volumes in the newborn period affects later development and behavior." The double-threat opioids pose to mothers and children Nearly 1 in 12 newborns in the United States in 2020 – or about 300,000 infants – were exposed to alcohol, opioids, marijuana or cocaine before they were born, according to the Substance Abuse and Mental Health Services Administration (SAMHSA). Prenatal substance exposure in rural areas often exceeds overall national averages. Opioids include illegal drugs like heroin and fentanyl, prescription drugs like oxycodone and hydrocodone, and medications for opioid use disorder like buprenorphine and methadone. Opioid use often goes hand in hand with smoking and use of other substances such as alcohol and marijuana. This study compared newborns born to mothers who took opioids only and newborns born to mothers who used other substances as well as opioids. Newborns exposed to opioids plus other substances had smaller brain volumes in more regions compared to those exposed to opioids only. The most common opioids among participants in the new study were buprenorphine (68.8%) and methadone (26%). Both of these opioids are routinely used to treat opioid use disorder (OUD) and are both recommended for treatment of OUD during pregnancy by the American College of Obstetricians and Gynecologists. "We know that buprenorphine and methadone are life-saving medications for women with OUD," Merhar says. "We don't want to imply that women with OUD should wean off these medications, but we agree with the ACOG recommendation for more research on medically supervised withdrawal in pregnant women." The study was praised in an accompanying editorial penned by Nethra Madurai, MD, and Lauren Jantzie, PhD, both of Johns Hopkins University School of Medicine. Other small studies have shown fetal brain changes caused by opioids. But this multi-center study is the first to be large enough to convincingly distinguish effects linked to opioids versus confounding factors such as maternal smoking, birth weight, education levels. The study authors "present compelling evidence of the direct effects of opioids on the developing brain," the editorial states. "Given the prospective design of the trial, they account for other postnatal factors…allowing us to dispel previous uncertainty surrounding the direct impacts of opioids on the brain vs the confounding effects of other environmental factors." What's next? Having more precise information about the affected parts of the brain could allow scientists to focus on interventions to support healthy brain development for children born after opioid exposure. "Indeed, we must shift our focus beyond the initial withdrawal symptoms associated with POE [prenatal opioid exposure] if we are to improve the lifelong health and well-being of infants and children impacted by the opioid epidemic," the editorial states. Read more about Merhar's research related to opioid exposure: 'Eat, Sleep, Console' Approach Slashes ICU Stays for Opioid-Exposed Newborns In Utero Opioid Exposure Impacts Fetal Brain Size and Development $8M Grant Funds Long-Term Opioid Exposure Study SOURCE Cincinnati Children's Hospital Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

07 Apr 2025

·www.prnewswire.com

Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

PITTSBURGH, April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability. Under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues. The Company had already accrued an estimate in respect of a potential settlement, which is reflected in the Company's annual report on Form 10-K for the year ended December 31, 2024. The Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids. For example, the Company manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. The Company is also developing a novel delivery for meloxicam, a non-opioid pain medication. The settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines. About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the Company's nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries; under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues; that the Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids; the Company is also developing a novel delivery for meloxicam, a non-opioid pain medication; and that the settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the inability or unwillingness on the part of any of the parties to agree to a final settlement; any legal or regulatory challenges to the settlement; the level of participation by litigants or claimants in the settlement framework; any failure by third parties to comply with their contractual obligations; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, tariffs and trade policies, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. SOURCE Viatris Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Patent Infringement

31 Mar 2025

·www.drugs.com

Evidence Supports Continuing Buprenorphine for Acute Pain in Those With Opioid Use Disorder

MONDAY, March 31, 2025 -- For patients with opioid use disorder (OUD), evidence supports continuation of buprenorphine during episodes of acute pain, but overall evidence for pain outcomes in these patients is low, according to a review published online March 18 in the Annals of Internal Medicine . Michele J. Buonora, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a systematic review to examine the benefits and harms of acute pain interventions among patients with OUD. A total of 17 trials, 20 controlled observational studies, and 78 uncontrolled observational studies met the criteria for eligibility. The researchers found that based on cohort studies conducted primarily in perioperative settings, there may be an association for continuing use of buprenorphine during acute pain episodes with similar or improved pain-related outcomes compared with discontinuation. In adults not prescribed medications for OUD, oral clonidine, intramuscular haloperidol and midazolam with intravenous morphine, and intraoperative intravenous lidocaine may improve pain outcomes based on single well-conducted randomized controlled trials in emergency department or perioperative settings; these findings warrant further study in diverse patient populations. Methadone and the effect of interventions on OUD outcomes were only assessed in a small percentage of studies. "The effects of acute pain management interventions on OUD outcomes have not been well characterized and merit urgent study in light of the ongoing crisis of opioid-related overdoses and other harms," the authors write.

Clinical Result

100 Deals associated with Buprenorphine

External Link

KEGG	Wiki	ATC	Drug Bank
D07132	Buprenorphine	N07BC01	DB00921

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Opioid-Related Disorders	United States	Braeburn, Inc.	23 May 2023
Opium Dependence	European Union	Camurus AB	20 Nov 2018
Opium Dependence	Iceland	Camurus AB	20 Nov 2018
Opium Dependence	Liechtenstein	Camurus AB	20 Nov 2018
Opium Dependence	Norway	Camurus AB	20 Nov 2018
Opioid abuse	United States	Indivior, Inc.	30 Nov 2017
Pain	United States	Purdue Pharma LP	13 Oct 2017
Chronic Pain	United States	Purdue Pharma LP	30 Jun 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Pain, Postoperative	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Cancer Pain	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
Intervertebral Disc Disease	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
opioid dependence methadone	Phase 3	United States	Titan Pharmaceuticals, Inc.	01 Sep 2008
Osteoarthritis, Knee	Phase 3	United States	Purdue Pharma LP	01 Sep 2007
Osteoarthritis	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Low Back Pain	Phase 3	United States	Purdue Pharma LP	01 Feb 2004
Irritable Bowel Syndrome	Phase 2	United States	OrphoMed, Inc.Startup	22 Nov 2019
Depressive Disorder, Major	Preclinical	China	Shenzhen Sciencare Medical Industries Co., Ltd.	27 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03605342 (CTgov)	Phase 2	Opioid abuse \| Stress Disorders, Post-Traumatic	38	Cognitive Processing Therapy (CPT)+Buprenorphine (Buprenorphine + CPT-C)	dhgmnaieew(vyuhvabzhh) = nhhglnfxwp nvjslkxyoy (dtdnniqcny, 2.62) View more	-	19 Aug 2024
				Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC)	dhgmnaieew(vyuhvabzhh) = rietqowhxl nvjslkxyoy (dtdnniqcny, 2.76) View more
NCT02651584 (PRNewswire) Manual	Phase 3	Opioid-Related Disorders	123	BRIXADI (fentanyl-positive)	rvhipfklok(kmtivxqiqm) = itjytatyve lqzbxbrwoo (txqalvoixz ) View more	Positive	25 Jun 2024
				buprenorphine + naloxone (fentanyl-positive)	rvhipfklok(kmtivxqiqm) = imbvxeujsk lqzbxbrwoo (txqalvoixz ) View more
NCT02651584 (Pubmed)	Phase 3	fentanyl-positive \| norfentanyl	428	Subcutaneous Buprenorphine	ujjxseyrrw(ajuqshgdmv) = rsqsoxcocn orkpnwchzf (ugdqepiemp )	Positive	03 Jun 2024
				Sublingual Buprenorphine-Naloxone	ujjxseyrrw(ajuqshgdmv) = arznstxtfw orkpnwchzf (ugdqepiemp )
NCT04254081 (ABCD&E, CTgov)	Phase 4	Anesthesia \| Pain, Procedural	57	Buprenorphine 0.15 MG (Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block)	seontpkscs(unoduumgww) = hdaulkrjik pvnjwjdnup (orscntadny, cdnqusvuuu - fyiacgevgx) View more	-	01 Aug 2023
				Lidocaine 1% Injectable Solution (1% Lidocaine Paracervical Block)	seontpkscs(unoduumgww) = lkbquganjy pvnjwjdnup (orscntadny, yvrhawmvkf - prtxrxzssz) View more
NCT02651584 (FDA) Manual	Phase 3	Opioid-Related Disorders	428	BRIXADI	hdrxkzdegl(kvffmxxuer) = vgjydnfjid nhmvluzgiq (kdgxeameex ) View more	Positive	23 May 2023
				buprenorphine/naloxone	hdrxkzdegl(kvffmxxuer) = pngtzsgvqx nhmvluzgiq (kdgxeameex ) View more
NCT02611752 (FDA) Manual	Phase 2	Opioid-Related Disorders	47	BRIXADI	gwtmphrxop(dnvynpcjak) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo fgvgkjyzuo (csnnxpxxgp )	Positive	23 May 2023
				Placebo
NCT02187198 (CTgov)	Phase 3	Opium Dependence	9	Buprenorphine (Buprenorphine Low Dose)	ftuulqnjfz = onpehjoipl gvmhhiaayc (oiktmvwdhn, nszjdkmqiv - bowjpjpvgh) View more	-	10 Mar 2023
				Buprenorphine (Buprenorphine High Dose)	ftuulqnjfz = whkmunbxzv gvmhhiaayc (oiktmvwdhn, tpectrbldq - kdzwjylryp) View more
NCT02543944 (GBN, CTgov)	Phase 2/3	Unspecified drug dependence	117	Naltrexone (depot)+Buprenorphine+Clonidine+Gabapentin+Naltrexone (oral) (Gabapentin)	yaunoyvvyd(bdnfrjtrxd) = ivwiywbceg cpgksnvlnv (bgxnwuwbqf, 36.7) View more	-	28 Jul 2022
				Placebo+Naltrexone (depot)+Buprenorphine+Clonidine+Naltrexone (oral) (Placebo)	yaunoyvvyd(bdnfrjtrxd) = lgqbssqglf cpgksnvlnv (bgxnwuwbqf, 38.5) View more
NCT03818399 (VOTIVE, CTgov)	Phase 3	Opiate Overdose \| Opioid abuse	19	SUBLOCADE	cibuprdmdh = rnjuhuhccz pfsqfshuoa (ouymecpumq, dxoqqokntl - qjjjjzerqs) View more	-	05 May 2022
NCT03608696 (B-PHORE, CTgov)	Phase 1/2	Neonatal Abstinence Syndrome	10	Buprenorphine	mapxskpkoz(eyfaapkzfw) = sscbmzrlhk slgtutxxsj (pivnybkbya, xmrbalodif - vlujyapgrg) View more	-	11 Feb 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis